Other

Julius-maximilians-universitat Wurzburg

Aridis Pharmaceuticals

Markus Haake

Simon Urwyler

Michael Rudolf

Jörg Wischhusen

Reinhard Dummer

Matthias Mehling

Tina Schäfer

Martina Selle

Michael Rodolf

The present invention relates to uses of inhibitors of human Growth and Differentiation Factor 15 (GDF-15), and to combined uses of such inhibitors with immune checkpoint blockers, in the treatment of solid cancers.

Combination therapy using inhibitors of human growth and differentiation factor 15 (GDF-15) and immune checkpoint blockers

The present invention relates to methods for predicting the probability of a treatment response of a human cancer patient to an immune checkpoint blocker treatment e.g. with anti PD-1, and to methods for predicting the probability of survival of a human cancer patient following an immune checkpoint blocker treatment, and to apparatuses and kits which can be used in these methods.

GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers

The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such asand compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.

Targets of

Targets of acinetobacter baumannii

[object Object]

Growing community of inventors

Bern, Switzerland

Markus Haake